Cardiff Oncology, Inc.CRDFNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average, structural decline.
Left:
||||
Year-over-year research & development expense growth
Latest
12.16%
↓ 49% below average
Average (9y)
23.81%
Historical baseline
Range
High:58.95%
Low:-47.47%
CAGR
-16.1%
Structural decline
| Period | Value |
|---|---|
| 2024 | 12.16% |
| 2023 | 21.21% |
| 2022 | 56.00% |
| 2021 | 54.66% |
| 2020 | 0.65% |
| 2019 | 36.73% |
| 2018 | 3.56% |
| 2017 | -47.47% |
| 2016 | 41.66% |
| 2015 | 58.95% |